Bruns Ingmar Insider Trades

Insider Trading History

Track insider trading activity for Bruns Ingmar. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals ZNTL
Chief Medical Officer
Holding Value $124k 33,332 shares
Last Trade
Feb 09, 2026 Sale (Open Market)Shares sold on the open market or in a private sale.
$801 335 shares
$2.39
$3.72
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals ZNTL
Chief Medical Officer
Holding Value $125k 33,667 shares
Last Trade
Feb 06, 2026 Sale (Open Market)Shares sold on the open market or in a private sale.
$7.2k 2,962 shares
$2.43
$3.72
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals ZNTL
Chief Medical Officer
Holding Value $1.36M 365,000 shares
Last Trade
Jan 08, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.04M 365,000 shares
$2.84
$3.72
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals ZNTL
Chief Medical Officer
Holding Value $136k 36,629 shares
Last Trade
Feb 06, 2025 Purchase (Open Market)Shares bought on the open market or in a private purchase outside of a company compensation plan.
$45.6k 20,000 shares
$2.28
$3.72
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals ZNTL
Chief Medical Officer
Holding Value $61.9k 16,629 shares
Last Trade
Feb 03, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$27.9k 16,629 shares
$1.68
$3.72
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals ZNTL
Chief Medical Officer
Holding Value $2.65M 712,650 shares
Last Trade
Dec 02, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.61M 712,650 shares
$3.66
$3.72

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up